TNFRSF1B and cancer: The different functions of TNFR2 as an oncogene and as an immune regulator of the TME open up to opposing strategies to target TNFR2 for cancer therapy, such as, on the one hand, inhibition of TNFR2 activities in immunosuppressive cells or TNFR2+ cancer cells or the TNFR2-dependent killing of these cells, and on the other hand, the stimulation of TNFR2 to exploit its proinflammatory activities, especially its co-stimulatory effect on CD8+ T-cells.